SELLAS’ CDK9 inhibitor to advance after “exceeding expectations” in AML
SELLAS Life Sciences’ CDK9 inhibitor, SLS009, for relapsed/refractory acute myeloid leukaemia (r/r AML) is set to advance after it met…
Oncology
-
-
Verastem’s avutometinib combination shows 31% ORR in ovarian cancer trial
Verastem Oncology has reported primary analysis data from the two-part multicentre Phase II RAMP 201 trial, demonstrating that avutometinib plus…
-
Dana-Farber’s trial shows improved immune response with cancer vaccine
Findings from a Phase I trial initiated by Dana-Farber Cancer Institute have demonstrated that the NeoVax personalised cancer vaccine’s updated…
-
Pfizer and Astellas’ Xtandi improves OS as combination therapy
Pfizer and Astellas’ Xtandi (enzalutamide) has improved overall survival (OS) in patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC), but only…
-
PDS Biotechnology completes recruitment for stage one of colorectal cancer trial
PDS Biotechnology has completed subject recruitment for stage one of its open-label Phase II trial, evaluating the systemic administration of…
-
MAIA Biotechnology doses first patient in expansion of Phase II lung cancer trial
US-based MAIA Biotechnology has dosed the first subject in Taiwan in the expansion phase of its multicentre THIO-101 Phase II…
-
CTO East Coast 2025: Global oncology cell therapy market to hit $25bn by 2031
According to GlobalData analysis, currently marketed and pipeline cell therapy assets in oncology will generate sales of around $25bn by…
-
UroGen concludes enrolment in Phase III trial of UGN-103 for bladder cancer
UroGen Pharma has completed the enrolment of subjects in its Phase III UTOPIA trial, which is evaluating UGN-103 (mitomycin) for…
-
PanTher Therapeutics launches second trial for chemotherapy patch
US-based PanTher Therapeutics has initiated a trial of its chemotherapy-eluting patch, which it hopes will make cancer therapy more tolerable. The…
-
Isomorphic Labs prepares to launch trials for AI-designed drugs
Alphabet's AI drug development subsidiary Isomorphic Labs is aiming to initiate clinical trials for its AI-developed oncology drugs. In an…
